Physician profile
Michael E Kader
NPI 1306854682
$7,463.50
in general payments reported to CMS, 2019-2025
34 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $389 · 2021: $849 · 2022: $1,092 · 2023: $1,440 · 2024: $1,035 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,975 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.97 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,783.74 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,391.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $548.13 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $505.26 | 2019-2025 | |
| Nuvasive, INC. | $485.67 | 2023 | Vuepoint, Reline, Xlif |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.77 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Ferring Pharmaceuticals INC. | $322.83 | 2019-2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $282.23 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $209.70 | 2019-2024 | Sutab, Suflave |
| Ardelyx, INC. | $189.74 | 2022-2025 | Ibsrela |
| Celgene Corporation | $187.76 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $144.42 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $124.12 | 2024-2025 | Vowst, Zenpep |
| Ipsen Biopharmaceuticals, INC | $105.14 | 2025 | Iqirvo |
| Qol Medical, LLC | $90.14 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $87.61 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $81.87 | 2019-2022 | |
| Exact Sciences Corporation | $62.77 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $56.70 | 2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $46.14 | 2025 | Voquezna |
| Genzyme Corporation | $44.63 | 2024-2025 | |
| Madrigal Pharmaceuticals | $40.61 | 2025 | Rezdiffra |
| Sandoz INC. | $39.16 | 2025 | Hyrimoz |
| Celltrion USA INC. | $34.04 | 2025 | Vegzelma |
| Daiichi Sankyo INC. | $33.95 | 2021-2022 | |
| Lilly USA, LLC | $31.53 | 2025 | Omvoh |
| Cook Medical LLC | $28.67 | 2021-2023 | Caesar |
| Intercept Pharmaceuticals, INC. | $28.16 | 2021 | |
| Merck Sharp & Dohme LLC | $27.53 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.41 | 2024 | Cyltezo |
| Organon LLC | $18.68 | 2024 | |
| Ucb, INC. | $16.11 | 2019 | |
| Endo Pharmaceuticals INC. | $13.89 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.